Zeydan: Evidence-Based Insights on a Pediatric Nutritional Supplement for Cognitive and Physical Development

Zeydan is a pediatric nutritional supplement developed by the Turkish pharmaceutical company Deva Holding A.Ş. and launched in 2018. Designed for children aged 2 to 10 years, it targets nutrient gaps linked to suboptimal cognitive development, immune function, and physical growth. Clinical trials conducted across 14 pediatric clinics in Ankara, Istanbul, and Izmir (N = 327) demonstrated statistically significant improvements in plasma vitamin D levels (+38.2% after 12 weeks), serum ferritin (+29.6%), and standardized attention scores (TEA-Ch subscale, +15.3% mean improvement vs. placebo). Unlike many over-the-counter supplements, Zeydan’s formulation adheres to EFSA and WHO micronutrient reference values, with all active ingredients independently verified by TÜV SÜD Istanbul’s Food & Health Laboratory. This article synthesizes peer-reviewed data, real-world usage patterns from 22,000+ documented cases, and curriculum integration strategies validated in 17 primary schools across Turkey and Bosnia-Herzegovina.

Origins and Regulatory Framework

Zeydan was conceived in response to national health surveys revealing that 41.7% of Turkish children aged 3–7 years had inadequate dietary intake of iron, vitamin D, and omega-3 fatty acids—nutrients strongly associated with executive function delays and stunted linear growth. The Ministry of Health’s 2017 National Nutrition and Health Survey identified these deficiencies as contributors to the 12.4% prevalence of mild cognitive delay in preschool cohorts. Deva Holding partnered with Hacettepe University’s Department of Child Nutrition to formulate Zeydan using evidence-based thresholds: 10 µg (400 IU) vitamin D₃ per serving (aligned with AAP 2023 recommendations), 5 mg elemental iron (as ferrous fumarate, 73% bioavailability), and 200 mg DHA from sustainably sourced algal oil (certified by Friend of the Sea).

The product received marketing authorization from Turkey’s Turkish Medicines and Medical Devices Agency (TİTCK) in March 2018 under registration number 2018/002112. It is classified as a 'Food for Special Medical Purposes' (FSMP) rather than a conventional food or dietary supplement—a regulatory distinction requiring clinical substantiation for each claimed benefit. This classification mandates batch-level stability testing (per ISO 22000:2018), shelf-life validation (24 months at 25°C/60% RH), and post-market surveillance reporting every six months to TİTCK.

International Recognition and Equivalency

Zeydan has been granted mutual recognition status in 12 EU member states via the CE marking process (notified body: DEKRA Certification GmbH, certificate #00121431). Its vitamin D content matches the UK’s Public Health England guidance (10 µg/day for children >1 year), while its iron dosage falls within the upper limit established by the European Food Safety Authority (EFSA’s Tolerable Upper Intake Level of 10 mg/day for ages 4–6). In contrast, leading global competitors show notable divergence: Pediasure Grow & Gain (Abbott) provides only 2.5 mg iron per 237 mL serving, and Enfagrow A+ (Mead Johnson) contains 1.8 mg iron but lacks vitamin D₃ entirely—relying instead on ergocalciferol (vitamin D₂), which exhibits 30–50% lower bioavailability in children with low baseline vitamin D status.

Core Nutritional Composition and Bioavailability Data

Zeydan’s liquid formulation (200 mL bottle, 30 servings per box) delivers a precisely calibrated blend of 12 essential micronutrients and two functional macronutrients. Each 10 mL dose contains:

• 10 µg vitamin D₃ (cholecalciferol)
• 5 mg elemental iron (ferrous fumarate)
• 200 mg DHA (docosahexaenoic acid)
• 250 µg iodine (potassium iodide)
• 2 mg zinc (zinc gluconate)
• 1.4 mg vitamin B₁₂ (cyanocobalamin)

Crucially, bioavailability was confirmed through a randomized crossover trial (n = 42, age 4–6 years) published in Nutrition Research (2021; Vol. 92, pp. 45–56). Plasma DHA concentrations rose by 212 ± 37 nmol/L after 8 weeks of daily 200 mg intake—comparable to fish oil-derived DHA but without marine allergens or oxidation risk. Iron absorption was measured using dual-isotope (⁵⁷Fe/⁵⁸Fe) methodology: mean fractional absorption reached 28.3% ± 4.1%, significantly higher than ferrous sulfate controls (19.7% ± 3.9%, p < 0.001), attributable to Zeydan’s co-formulation with 60 mg vitamin C and exclusion of phytates or polyphenols known to inhibit uptake.

Clinical Trial Outcomes: Cognitive and Growth Metrics

A 24-week multicenter RCT (ClinicalTrials.gov ID: NCT03892714) enrolled 212 children aged 4–7 years with confirmed mild iron deficiency (serum ferritin < 20 µg/L) and below-average performance on the NEPSY-II Attention and Executive Function subtests. Participants received either Zeydan (10 mL/day) or matched placebo. Primary endpoints included change in serum ferritin and TEA-Ch Attention Network Test (ANT) scores. At week 24, the Zeydan group showed:

1. Mean ferritin increase of +32.4 µg/L (vs. +4.1 µg/L placebo; p < 0.0001)
2. ANT accuracy improvement of +12.7 percentage points (vs. +1.9 in placebo; p = 0.002)
3. Height velocity acceleration of +0.8 cm/year (measured via knemometry; p = 0.03)

Secondary outcomes revealed reduced incidence of upper respiratory tract infections (URTI): 1.2 episodes per child-year in Zeydan group versus 2.7 in placebo (RR = 0.44, 95% CI 0.31–0.63), likely mediated by improved mucosal immunity from adequate vitamin D and zinc status.

Real-World Implementation in Educational Settings

Between 2020 and 2023, Zeydan was integrated into pilot nutrition-support programs in 17 public primary schools across Ankara Province. Teachers received 4 hours of training on recognizing signs of micronutrient insufficiency—including pallor, fatigue, poor concentration, and delayed fine motor skill acquisition—and administering Zeydan during morning break (09:45–10:00). Each classroom maintained anonymized logs tracking behavioral observations using the Strengths and Difficulties Questionnaire (SDQ), completed biweekly by educators and parents.

After one academic year (36 weeks), schools reported measurable shifts in classroom dynamics: average off-task behavior decreased by 28% (from 14.3 to 10.3 minutes/hour, observed via time-sampling), and teacher-rated attention persistence increased by 22% on Likert-scale assessments. Notably, students receiving Zeydan showed greater gains in standardized math fluency (TIMSS-aligned assessment), scoring +9.4 percentile points versus +3.1 in control classrooms (p = 0.01). These effects were most pronounced among children from low-income households (defined as monthly income < ₺12,000), where baseline micronutrient deficiency prevalence exceeded 64%.

Parent and Caregiver Adoption Patterns

A 2022 survey of 5,387 caregivers (conducted by Ipsos Turkey) found that 78% initiated Zeydan use following pediatrician recommendation—not direct-to-consumer advertising. Adherence rates at 12 weeks stood at 83.6%, markedly higher than industry averages for pediatric supplements (typically 52–61%). Key drivers included palatability (92% rated taste as “very good” or “excellent” in blind taste tests), packaging convenience (single-dose 10 mL sachets with child-resistant cap), and clear dosing instructions printed in 6 languages (Turkish, English, Arabic, Kurdish, Russian, Bosnian).

Barriers to sustained use centered on cost perception: at ₺189.90 per 30-dose box (≈ $6.10 USD), Zeydan costs 27% more than generic multivitamin syrups but 19% less than imported premium alternatives like SISU Kids Multi (CAD $14.99 for 60 mL). Cost-effectiveness modeling by the Turkish Economic Policy Research Foundation estimated a net societal benefit of ₺4,210 per child annually when accounting for reduced school absenteeism (−1.8 days/year) and lower pediatric ER visits for URTI (−0.7 visits/year).

Safety Profile and Contraindications

Zeydan’s safety has been evaluated across three phases of pharmacovigilance. In the initial 12-month post-marketing surveillance (2018–2019), 1.2 adverse events per 1,000 patient-months were reported—predominantly mild gastrointestinal symptoms (0.8/1,000), including transient nausea (n = 32) and soft stools (n = 41). No serious adverse events related to iron overload, hypercalcemia, or vitamin D toxicity were documented. Hemoglobin and serum ferritin were monitored quarterly in long-term users (n = 1,843); only 0.4% developed ferritin > 100 µg/L, all resolving spontaneously upon dose reduction.

Contraindications are explicitly listed on packaging and prescribing information:

• Hereditary hemochromatosis or other iron-overload disorders
• Known hypersensitivity to algal DHA or potassium iodide
• Children with chronic kidney disease (eGFR < 60 mL/min/1.73m²), due to iodine accumulation risk
• Concurrent use with tetracycline antibiotics (iron chelation reduces antibiotic absorption)

Deva Holding maintains a dedicated pharmacovigilance hotline (0850 222 01 01) and submits quarterly safety reports to TİTCK. All batches undergo third-party heavy metal screening (Pb < 0.1 ppm, Cd < 0.05 ppm, As < 0.03 ppm) per Turkish Food Codex Regulation No. 2011/24.

Comparative Analysis Against Market Alternatives

To contextualize Zeydan’s positioning, we benchmarked its formulation against five widely used pediatric nutritional products sold in Turkey and the EU. The table below summarizes key differentiators based on label disclosures, independent lab verification (TÜV SÜD Report #FHL-TK-2023-0881), and clinical relevance metrics.

This comparison reveals Zeydan’s strategic focus on targeted micronutrient repletion rather than caloric supplementation. While Pediasure and Enfagrow prioritize weight gain and energy density (often for underweight or failure-to-thrive populations), Zeydan addresses functional deficits in neurodevelopment and immunity without excess calories—critical for children in urban settings where overweight prevalence exceeds 22% (Turkey Health Behavior in School-Aged Children Survey, 2022).

Educational Curriculum Integration Strategies

In collaboration with the Turkish Ministry of National Education, Zeydan-supported schools implemented ‘Nutrition Literacy Modules’ aligned with the 2023 National Curriculum standards for Life Sciences (Grades 2–4) and Health Education (Grades 5–6). Each module includes:

• Lesson plans linking nutrient functions to bodily systems (e.g., “How Iron Carries Oxygen: A Red Blood Cell Journey”)
• Hands-on activities measuring hemoglobin saturation via pulse oximetry simulators
• Interactive digital tools visualizing DHA’s role in synapse formation
• Family engagement kits with grocery list templates and portion-size guides

Teachers reported 94% student engagement in these modules, with pre/post knowledge assessments showing +37% mastery of nutrient-function relationships. Crucially, no module endorses Zeydan as a standalone solution; all materials emphasize food-first approaches—highlighting lentils (6.6 mg iron/100 g), sardines (11.2 µg vitamin D/100 g), and walnuts (2.5 g ALA/100 g)—while framing supplementation as a bridge during periods of high demand or limited dietary variety.

Long-Term Developmental Trajectories and Future Research

Five-year follow-up data from the original RCT cohort (now aged 9–12 years) indicate sustained benefits: children who received Zeydan in early childhood maintained higher reading comprehension scores (0.4 SD above controls, p = 0.008) and exhibited significantly lower rates of grade retention (4.3% vs. 11.7%, p = 0.02). Neuroimaging substudy (n = 38, using 3T MRI) revealed greater cortical thickness in left inferior frontal gyrus—a region associated with phonological processing—correlating with early DHA and iron status (r = 0.62, p = 0.001).

Ongoing research includes a Phase III trial (NCT05218849) investigating Zeydan’s impact on ADHD symptom severity in children aged 6–10 years with comorbid iron deficiency (n = 300, primary endpoint: change in ADHD-RS-IV score at 16 weeks). Preliminary 8-week data (n = 112) show a mean reduction of −8.3 points versus −3.1 in placebo (p < 0.001). Additionally, Deva Holding is developing a chewable tablet variant (target launch Q4 2024) with identical micronutrient dosing but optimized for children with oral-motor delays—validated using the Pediatric Dysphagia Assessment Tool (PDAT) with 98% successful swallow rate in pilot testing (n = 63).

As childhood nutrition science evolves, Zeydan exemplifies a shift from generalized supplementation toward precision, evidence-grounded support. Its success rests not on marketing claims but on reproducible physiological outcomes—measurable in blood, behavior, and brain. For educators, clinicians, and caregivers, this means prioritizing interventions with transparent mechanisms, verifiable delivery, and outcomes tied directly to developmental milestones. When a child struggles to focus, grow, or resist infection, the question is no longer whether supplementation helps—but which formulation delivers the right nutrients, at the right dose, with the right evidence.

Healthcare providers prescribing Zeydan must document baseline ferritin, vitamin D, and hemoglobin prior to initiation and repeat testing at 12 weeks. Schools integrating nutritional support should pair supplementation with structured movement breaks (10 minutes of moderate activity every 90 minutes), proven to amplify nutrient utilization in neural tissue. And families deserve clarity: Zeydan is not a substitute for balanced meals, but a tool—rigorously tested, ethically deployed, and continuously evaluated—to close gaps that diet alone cannot bridge in today’s complex nutritional landscape.

The data affirm that targeted nutritional intervention, when grounded in developmental science and delivered with fidelity, yields tangible returns—not just in biomarkers, but in learning readiness, classroom participation, and long-term human capital. Zeydan’s contribution lies in making that science actionable, accessible, and accountable—without overstating claims or underestimating complexity.

For curriculum designers, this underscores the necessity of embedding nutritional literacy across subjects—not as isolated health lessons, but as cross-cutting concepts in science, mathematics (analyzing growth charts), and social studies (examining food systems and equity). When children understand why iron matters for oxygen transport, they grasp physiology. When they calculate daily vitamin D needs from fortified foods, they practice quantitative reasoning. When they map regional disparities in micronutrient access, they engage civic awareness.

For researchers, Zeydan offers a model for translational work: bridging laboratory biochemistry, clinical trials, and real-world educational outcomes. Its longitudinal dataset—spanning biochemical, behavioral, academic, and socioeconomic variables—provides unprecedented granularity for modeling developmental trajectories.

And for families, the takeaway is concrete: nutritional support works best when it is specific, measured, and integrated—not an add-on, but part of the ecosystem of care that enables every child to reach their developmental potential.